Becton, Dickinson and Company $BDX Shares Bought by Nisa Investment Advisors LLC

Key Points

• Nisa Investment Advisors increased its Becton, Dickinson and Company stake by 18.9% in the third quarter, bringing its holdings to 80,374 shares valued at approximately $14.4 million. Institutional investors collectively own 86.97% of BDX.
• BDX reported quarterly revenue of $4.98 billion and earnings of $3.23 per share, exceeding analyst expectations, while revenue rose 5.4% year over year. The company guided to fiscal 2026 earnings of $12.62–$12.72 per share.
• The stock recently traded near its 52-week high at $194.29, while analysts maintain a consensus “Hold” rating and an average price target of $185.07. BDX also pays a $1.05 quarterly dividend, though its payout ratio is elevated at 126.51%.

Nisa Investment Advisors LLC raised its stake in shares of Becton, Dickinson and Company (NYSE:BDX - Free Report) by 18.9% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 80,374 shares of the medical instruments supplier's stock after acquiring an additional 12,798 shares during the period. Nisa Investment Advisors LLC's holdings in Becton, Dickinson and Company were worth $14,387,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Brown Lisle Cummings Inc. lifted its holdings in shares of Becton, Dickinson and Company by 9.2% in the 2nd quarter. Brown Lisle Cummings Inc. now owns 644 shares of the medical instruments supplier's stock worth $97,000 after acquiring an additional 54 shares during the last quarter. Pension & Wealth Management Advisors Inc. boosted its position in shares of Becton, Dickinson and Company by 12.3% during the 3rd quarter. Pension & Wealth Management Advisors Inc. now owns 510 shares of the medical instruments supplier's stock worth $94,000 after purchasing an additional 56 shares during the period. Elevation Point Wealth Partners LLC increased its holdings in Becton, Dickinson and Company by 3.7% in the 2nd quarter. Elevation Point Wealth Partners LLC now owns 1,692 shares of the medical instruments supplier's stock valued at $256,000 after purchasing an additional 60 shares during the last quarter. Private Harbour Investment Management & Counsel LLC increased its holdings in Becton, Dickinson and Company by 1.1% in the 2nd quarter. Private Harbour Investment Management & Counsel LLC now owns 5,511 shares of the medical instruments supplier's stock valued at $834,000 after purchasing an additional 62 shares during the last quarter. Finally, NorthRock Partners LLC raised its position in Becton, Dickinson and Company by 2.0% in the second quarter. NorthRock Partners LLC now owns 3,295 shares of the medical instruments supplier's stock valued at $499,000 after purchasing an additional 65 shares during the period. 86.97% of the stock is owned by hedge funds and other institutional investors.

Becton, Dickinson and Company Trading Up 0.3%

NYSE BDX opened at $194.29 on Thursday. The firm has a 50 day simple moving average of $184.73 and a 200-day simple moving average of $164.54. The company has a debt-to-equity ratio of 0.55, a quick ratio of 0.51 and a current ratio of 0.87. Becton, Dickinson and Company has a one year low of $127.59 and a one year high of $195.99. The firm has a market cap of $53.53 billion, a price-to-earnings ratio of 58.52, a PEG ratio of 13.07 and a beta of 0.21.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last announced its quarterly earnings data on Thursday, August 6th. The medical instruments supplier reported $3.23 earnings per share for the quarter, beating analysts' consensus estimates of $3.14 by $0.09. Becton, Dickinson and Company had a net margin of 4.52% and a return on equity of 14.79%. The firm had revenue of $4.98 billion during the quarter, compared to analysts' expectations of $4.89 billion. During the same quarter in the previous year, the business posted $3.68 earnings per share. The business's quarterly revenue was up 5.4% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. Equities research analysts anticipate that Becton, Dickinson and Company will post 12.67 EPS for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Wednesday, September 30th. Shareholders of record on Wednesday, September 9th were given a $1.05 dividend. This represents a $4.20 annualized dividend and a yield of 2.2%. The ex-dividend date of this dividend was Wednesday, September 9th. Becton, Dickinson and Company's dividend payout ratio (DPR) is currently 126.51%.

Insiders Place Their Bets

In other news, EVP Roland Goette sold 2,438 shares of the stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $180.84, for a total value of $440,887.92. Following the sale, the executive vice president directly owned 14,856 shares in the company, valued at approximately $2,686,559.04. This trade represents a 14.10% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Michael Feld sold 165 shares of Becton, Dickinson and Company stock in a transaction on Wednesday, August 26th. The shares were sold at an average price of $188.49, for a total value of $31,100.85. Following the completion of the transaction, the executive vice president owned 19,720 shares of the company's stock, valued at approximately $3,717,022.80. This trade represents a 0.83% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 6,906 shares of company stock worth $1,265,855 over the last 90 days. Corporate insiders own 0.40% of the company's stock.

Wall Street Analyst Weigh In

BDX has been the topic of a number of research reports. Wells Fargo & Company upped their price target on Becton, Dickinson and Company from $161.00 to $170.00 and gave the stock an "equal weight" rating in a research note on Friday, August 7th. Wolfe Research began coverage on Becton, Dickinson and Company in a research report on Tuesday. They set an "outperform" rating for the company. Citigroup reaffirmed a "buy" rating on shares of Becton, Dickinson and Company in a research note on Thursday, August 13th. Barclays initiated coverage on Becton, Dickinson and Company in a report on Wednesday, October 7th. They issued an "underweight" rating and a $165.00 price objective on the stock. Finally, Evercore set a $180.00 target price on Becton, Dickinson and Company in a research note on Monday, July 6th. Eight investment analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus target price of $185.07.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company, commonly known as BD, is a global medical technology company that develops, manufactures and sells a broad range of products used by healthcare providers, clinical laboratories, pharmaceutical companies and patients. Its offerings support medication delivery, diagnostics, infection prevention, surgical care and other clinical procedures.

BD's products include needles, syringes, injection devices, intravenous administration systems, medication-management technologies, specimen-collection products, diagnostic systems and laboratory instruments.

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.